Shenwan Hongyuan: First issued a "buy" rating on Basse Osei Tu-B (02315.HK) AI+ empowers global new drug development.

Wisdom Financial APP learned that Shenwan Hongyuan issued a research report stating that it is expected that the net profit attributable to the parent company of 3SBio-B (02315.HK) will be 423 million, 661 million, and 956 million respectively in 2026-2028, with year-on-year growth rates of 144.07%, 56.3%, and 44.68% respectively. Comparable companies such as Zhaoyan Pharmaceutical, Chengdu Leader, and Yaokang Biotechnology were selected based on the company's sector and main business. Currently, the company's stock price corresponds to a 38 times PE ratio for 2026, giving the company an average valuation of 47 times PE for 2026, with a corresponding market value of 22.8 billion Hong Kong dollars, currently valued at 18.3 billion Hong Kong dollars, representing a 24.5% increase potential. It is recommended to buy for the first time coverage.